Actovegin in the management of patients after ischemic stroke: A systematic review.

Abstract

BACKGROUND:

Actovegin is a hemodialysate of calf's blood and has been used for several decades in the countries of Central Asia, East Asia, Russia and some European countries. It has been used to treat patients with various neurological conditions, vascular disorders, and ischemic stroke.

OBJECTIVES:

To perform a systematic review to evaluate the effect of Actovegin in patients who have suffered an ischemic stroke.

METHODS:

A search of MEDLINE, PubMed, Cochrane and Embase was carried out from inception to October 10, 2021 for clinical trials and observational studies with a control group, published in English or Russian.

RESULTS:

Of 220 identified unique records, 84 full-text articles were screened, and 5 studies were selected that met the inclusion criteria. This included 4 observational studies with control groups and one randomized, placebo-controlled clinical trial. These studies enrolled a total of 3879 patients of which 720 patients received Actovegin administered intravenously and/or orally for a duration ranging from 10 to 180 days. Because of study heterogeneity, meta-analysis was not performed. No consistent evidence on improved survival, quality of life, neurologic symptoms, activities of daily living or disability was identified. One study showed statistically significant improvements in the Alzheimer's Disease Assessment Scale, cognitive subscale, extended version (ADAS-cog+) for Actovegin compared with placebo at 6 months but the clinical relevance of this change is uncertain. One study reported a higher incidence of recurrent ischemic stroke, transient ischemic attack or intracerebral hemorrhage in patients taking Actovegin compared to placebo.

CONCLUSIONS:

The benefits of Actovegin are uncertain and that there is potential risk of harm in patients with stroke. More evidence is needed from rigorously designed clinical trials to justify the role of Actovegin in patients with ischemic stroke.

• Authors: Philip la Fleur, Ardak Baizhaxynova, Emily Reynen, David Kaunelis, Dinara Galiyeva
• Journal: PloS one (PLoS One) Vol. 17 Issue 6 Pg. e0270497 ( 2022) ISSN: 1932-6203 [Electronic] United States
• PMID: 35771887 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Heme
• Actovegin

Topics

• Activities of Daily Living
• Heme (analogs & derivatives)
• Humans
• Ischemic Attack, Transient
• Ischemic Stroke
• Observational Studies as Topic
• Quality of Life
• Randomized Controlled Trials as Topic
• Stroke (drug therapy)